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A B S T R A C T
AZD2563, a new oxazolidinone targeted at Gram-positive bacteria, was evaluated and compared with
linezolid and other agents against 802 aerobic bacterial isolates for spectrum of activity, bactericidal
activity, and the effect of miscellaneous factors upon activity in vitro. At a concentration of 2 mg ⁄L,
AZD2563 inhibited 98% of all Gram-positive bacteria tested (100% at 4 mg ⁄L), including susceptible and
resistant isolates of Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus spp., Strepto-
coccus pneumoniae, other Streptococcus spp. and Corynebacterium spp. Conversely, all Enterobacteriaceae
and non-fermenting Gram-negative bacteria had MICs > 128 mg ⁄L, and only a few Haemophilus or
Moraxella spp. had MICs < 8 mg ⁄L. By conventional laboratory definition, AZD2563 and linezolid were
bacteriostatic against staphylococci and enterococci, with variable bactericidal activity against Strep.
pneumoniae. The in-vitro activity of AZD2563 was essentially unaffected by altering pH, inoculum size,
the type of testing medium, or the inclusion of human serum up to 25% v ⁄ v.
Keywords Oxazolidinones, in-vitro properties, MICs, bactericidal activity, bacteriostatic activity
Original Submission: 16 October 2002; Revised Submission: 11 February 2003; Accepted: 12 March 2003
Clin Microbiol Infect 2004; 10: 247–254
I N T R O D U C T I O N
The ability of bacteria to evade the action of
virtually all antibacterial classes is such that
resistance is almost inevitable, and this situation
is not helped by practices such as poor prescri-
bing. Currently, a specific clinical concern is the
emergence of resistance in Gram-positive organ-
isms, including methicillin resistance in staphy-
lococci [1], vancomycin-intermediate resistance in
Staphylococcus aureus [2], vancomycin resistance in
enterococci [3], and reduced penicillin suscepti-
bility in the pneumococci [4].
AZD2563 is a new oxazolidinone (Fig. 1),
identified from an antibiotic research programme
which aimed to synthesise agents that inhibited
all Gram-positive bacteria, including multiresist-
ant strains likely to be encountered clinically. No
activity against Enterobacteriaceae was expected,
and analogues with marginal activity against
Haemophilus or Moraxella spp. were rejected.
AZD2563 also has the potential for once-daily
dosing by both the oral and parenteral routes,
supported by in-vivo data [5–7].
This paper describes the in-vitro properties of
AZD2563, including its spectrum of activity,
bactericidal activity, and the effect of miscellane-
ous factors upon its activity in vitro.
M A T E R I A L S A N D M E T H O D S
Antimicrobial agents
The agents tested were AZD2563 (AstraZeneca, Macclesfield,
UK), linezolid, quinupristin–dalfopristin, levofloxacin, clarith-
romycin, vancomycin and teicoplanin. AZD2563 and all other
agents were obtained from their respective manufacturers or
from Sigma-Aldrich (Poole, UK). All agents, their weights
corrected for potency, were dissolved in dimethylsulphoxide,
and dilutions were prepared in broth or agar on the same
day.
Corresponding author and reprint requests: P. J. Turner,
Antibiotic Development and Technical Support Group, Astra-
Zeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10
4TG, UK
E-mail: philip.turner@astrazeneca.com
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
Bacterial isolates
In total, 802 clinical isolates were obtained from hospital
laboratories in North America and Europe, to which the
Mu50 VISA strain [8] was added. The isolates were deemed
to be pathogenic by the reporting laboratories, and were
identified in accordance with standard procedures. This
collection was unselected, but did contain many isolates
resistant to conventional antimicrobial agents. Both sensitive
and resistant isolates were included for each major class of
organism; in particular, isolates of S. aureus resistant to
methicillin and other agents, and isolates of Enterococcus
faecalis and Enterococcus faecium resistant to vancomycin,
were included. Isolates were stored either frozen at ) 70 C
on beads, or in glycerol 10% v ⁄v broth in liquid nitrogen.
All isolates were cultured on a non-selective medium before
testing.
MICs for all isolates were determined, with minimum
bactericidal concentrations (MBCs) determined for 57 isolates.
Five recent Gram-positive clinical isolates and one reference
strain were used in time–kill studies. To assess miscellaneous
effects upon MICs, four reference strains were used: methicil-
lin-sensitive S. aureus ATCC 29213; methicillin-resistant
S. aureus ATCC 3300; Staphylococcus epidermidis ATCC 12228;
and E. faecalis ATCC 29212.
MIC testing methods
National Committee for Clinical Laboratory Standards
(NCCLS) methodology [9] was employed, with Mueller–
Hinton agar (MHA; Difco, Detroit, MI, USA) for staphylococci,
enterococci, coliforms and ‘non-fermenting’ Gram-negatives;
MHA containing sheep blood 5% v ⁄v for non-pneumococcal
streptococci; MHA containing horse blood 5% v ⁄v for Coryne-
bacterium spp.; Mueller–Hinton broth (MHB; Difco) containing
lysed horse blood 5% v ⁄v for pneumococci; and Haemophilus
Test Medium (Oxoid, Basingstoke, UK) for Haemophilus influ-
enzae and Moraxella catarrhalis. Incubation times, atmosphere
and temperature were in accordance with NCCLS guidelines
[9]. ATCC quality control strains were included in each set of
tests.
MBCs
For this purpose, MICs were determined by broth dilution in
MHB for staphylococci and enterococci, and in MHB con-
taining lysed horse blood 5% v ⁄v for pneumococci. The
bacterial inoculum was 5 · 105 CFU ⁄mL, as judged by
reference to an opacity standard. MICs were determined
after overnight incubation in an appropriate environment,
with an endpoint of no visible growth. The MBC was then
determined by transferring 100 lL (with a 1 : 10 dilution to
avoid antibiotic carryover) from wells with no growth on to
agar plates, and observing growth and colony counts after
overnight incubation. The MBC was defined as the lowest
concentration of a compound that reduced the starting
inoculum from 5 · 105 CFU ⁄mL to £ 5 · 102 CFU ⁄mL, as
determined by viable counts.
Time–kill studies
One isolate each of S. aureus, S. epidermidis, E. faecalis,
E. faecium and Strep. pneumoniae, together with the reference
strain Strep. pneumoniae ATCC 49619, were studied. These
isolates were included among the 57 isolates tested for MBCs.
MHB (plus lysed horse blood 5% v ⁄v for pneumococci) was
used throughout, with viable counts performed on MHA
(plus whole horse blood 5% v ⁄v for pneumococci). AZD2563,
linezolid or vancomycin were added to conical flasks con-
taining 50 mL of logarithmically growing cultures at a
density of 5 · 105 CFU ⁄mL, as judged by reference to an
opacity standard, so that the following final concentrations of
their respective MICs were achieved: 0.5 · MIC, 1 · MIC,
2 · MIC, 4 · MIC, 8 · MIC, and a growth control containing
no antibiotic. Viable counts were determined (in duplicate) 0,
2, 4, 8 and 24 h after addition of the antibiotic. Strep.
pneumoniae viable counts were not done at 24 h because of
the autolytic nature of the organism [10]. The bacteria were
enumerated after incubation for 24 h at 35–37 C. Time–kill
graphs were plotted as log10 CFU ⁄mL against the five time
points at 4 · MIC, in accordance with recent practice [11],
following reaffirmation of MICs.
Studies of effects of miscellaneous factors on activity
The influence of inoculum size on the MICs for the four
reference strains listed above was assessed with a bacterial
challenge of 103, 104, 105 and 106 CFU ⁄ inoculum spot on MHA.
Any influence of medium was assessed by determining MICs
on MHA, as well as on IsoSensitest, Nutrient and Tryptone
Soya agar (Oxoid). The effect of pH on MIC was assessed with
MHA and MHB adjusted to pH 5, 6, 7 or 8. The impact of serum
on MICs was investigated with MHB to which human serum
10% or 25% v ⁄v was added.
R E S U L T S
MICs: activity and spectrum
The susceptibilities of the 802 isolates to AZD2563
and comparators are presented in Table 1. At
4 mg ⁄L, AZD2563 inhibited all isolates of staphy-
lococci, enterococci, streptococci and corynebacte-
ria, while 98% of isolates were inhibited at
2 mg ⁄L. AZD2563 was uniformly active against
oxacillin-resistant and -susceptible strains of
S. aureus, S. epidermidis and other coagulase-neg-
ative staphylococci. Activity was as great against
vancomycin-resistant enterococci and penicillin-
resistant pneumococci as against fully antibiotic-
susceptible strains. Similarly, potency was not
reduced against isolates resistant to levofloxacin
and ⁄ or clarithromycin.
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Fig. 1. Structure of AZD2563.
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Table 1. Activities of AZD2563 and
comparator agents against 802 clin-
ical isolates Organism (no. tested) Antibiotic
MIC (mg ⁄L)
Range MIC50 MIC90
Staphylococcus aureus,
oxacillin-susceptible (76)
AZD2563
Linezolid
0.125–2
1–4
0.5
2
1
2
Quinupristin–dalfopristin 0.25–1 0.5 0.5
Levofloxacin 0.06–8 0.25 0.5
Clarithromycin 0.06 to > 128 0.25 32
Vancomycin 1–2 1 2
Teicoplanin 0.25–4 1 2
Staphylococcus aureus,
oxacillin-resistant (40)
AZD2563
Linezolid
0.125–2
1–4
1
2
2
2
Quinupristin–dalfopristin 0.25–1 0.5 1
Levofloxacin 0.06–32 8 16
Clarithromycin 0.5 to > 128 16 > 128
Vancomycin 0.5–2 1 2
Teicoplanin 0.25–2 1 2
Staphylococcus epidermidis,
oxacillin-susceptible (70)
AZD2563
Linezolid
0.125–2
0.5–4
1
1
2
2
Quinupristin–dalfopristin 0.06–1 0.25 1
Levofloxacin 0.06–32 0.25 0.5
Clarithromycin 0.015 to > 128 0.13 > 128
Vancomycin 0.5–4 2 4
Teicoplanin 0.25–8 1 2
Staphylococcus epidermidis,
oxacillin-resistant (45)
AZD2563
Linezolid
0.06–2
0.5–4
0.5
1
1
2
Quinupristin–dalfopristin 0.125–4 0.25 1
Levofloxacin 0.06–64 0.5 16
Clarithromycin 0.06 to > 128 0.25 > 128
Vancomycin 0.06–4 2 4
Teicoplanin 0.25–4 1 4
Coagulase-negative
staphylococci,
oxacillin-susceptible (6)
AZD2563
Linezolid
Quinupristin–dalfopristin
0.25–1
1–4
0.25–0.5
0.5
4
0.5
1
4
0.5
Levofloxacin 0.125–32 0.25 32
Clarithromycin 0.06 to > 128 0.125 > 128
Vancomycin 0.5–2 1 2
Teicoplanin 0.25–8 0.5 8
Coagulase-negative
staphylococci,
oxacillin-resistant (40)
AZD2563
Linezolid
Quinupristin–dalfopristin
0.125–2
1–4
0.25–1
1
2
0.5
2
4
0.5
Levofloxacin 0.125 to > 128 8 > 128
Clarithromycin 0.5 to > 128 16 > 128
Vancomycin 0.5–4 2 4
Teicoplanin 0.015 to > 128 8 32
Enterococcus faecalis,
vancomycin-susceptible (50)
AZD2563
Linezolid
2–4
1–4
2
4
4
4
Quinupristin–dalfopristin 0.5–64 8 8
Levofloxacin 0.25–128 2 64
Clarithromycin 0.125 to > 128 2 > 128
Vancomycin 1–4 2 4
Teicoplanin 0.06–1 0.25 1
Enteroccus faecalis,
vancomycin-resistant (20)
AZD2563
Linezolid
2–4
4
2
4
4
4
Quinupristin–dalfopristin 0.25–32 8 16
Levofloxacin 2–64 32 64
Clarithromycin 0.5 to > 128 > 128 > 128
Vancomycin 8 to > 128 128 > 128
Teicoplanin 0.06 to > 128 0.5 > 128
Enterococcus faecium,
vancomycin-susceptible (52)
AZD2563
Linezolid
0.5–2
2–4
2
4
2
4
Quinupristin–dalfopristin 0.5–16 1 4
Levofloxacin 2 to > 128 8 128
Clarithromycin 0.03 to > 128 > 128 > 128
Vancomycin 0.5–4 1 2
Teicoplanin 0.03–1 0.5 1
Enterococcus faecium,
vancomycin-resistant (23)
AZD2563
Linezolid
2–4
2–4
2
2
2
4
Quinupristin–dalfopristin 0.125–2 1 2
Levofloxacin 1–128 4 128
Clarithromycin 2 to > 128 > 128 > 128
Vancomycin 2 to > 128 > 128 > 128
Teicoplanin 0.25–128 32 128
Streptococcus pneumoniae,
penicillin-susceptible (33)
AZD2563
Linezolid
0.06–0.5
0.06–1
0.5
0.5
0.5
0.5
Quinupristin–dalfopristin 0.06–0.5 0.125 0.25
Levofloxacin 0.25–1 0.5 0.5
Clarithromycin 0.06 0.06 0.06
Vancomycin 0.06–0.5 0.25 0.25
Teicoplanin 0.06 0.06 0.06
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AZD2563 had no activity against Enterobacte-
riaceae, non-fermenting organisms (including
Pseudomonas aeruginosa), the nutritionally fastidi-
ous Gram-negative bacterium H. influenzae, and
had only weak activity against M. catarrhalis.
Many of the Gram-positive strains were resist-
ant to one or more of the comparator agents.
However, according to NCCLS criteria, 90% were
susceptible to both oxazolidinones tested. MIC90
values for AZD2563 were comparable, or one
dilution more potent, than those for linezolid.
MIC50 data showed AZD2563 to be one dilution
more potent than linezolid for most classes
of Gram-positive bacteria (Fig. 2). However,
AZD2563 was less potent against H. influenzae
and M. catarrhalis.
MBCs
The results, expressed as a multiple of the MIC,
showed that there was variation between strains
within a genus for both AZD2653 and linezolid
(Table 2). The MBC ⁄MIC ratio values against
the pneumococci were generally lower, while
Table 1. Continued
Organism (no. tested) Antibiotic
MIC (mg ⁄L)
Range MIC50 MIC90
Streptococcus pneumoniae,
penicillin-resistant (41)
AZD2563
Linezolid
0.06–1
0.06–1
0.25
0.5
0.5
0.5
Quinupristin–dalfopristin 0.06–1 0.25 0.25
Levofloxacin 0.25–1 0.5 0.5
Clarithromycin 0.06 to > 128 0.06 > 128
Vancomycin 0.06–0.5 0.125 0.25
Teicoplanin 0.06 0.06 0.06
Streptococcus pyogenes (42) AZD2563 0.25–1 0.5 1
Linezolid 1 1 1
Quinupristin–dalfopristin 0.125–0.5 0.25 0.5
Levofloxacin 0.25–4 0.5 2
Clarithromycin £ 0.06–128 £ 0.06 £ 0.06
Vancomycin 0.5–1 0.5 1
Teicoplanin £ 0.06 £ 0.06 £ 0.06
Other b-haemolytic
streptococci (15)
AZD2563
Linezolid
0.125–2
0.5–2
1
2
2
2
Quinupristin–dalfopristin 0.125–1 0.5 1
Levofloxacin 1–2 2 2
Clarithromycin £ 0.06–32 0.125 0.25
Vancomycin 0.5–1 1 1
Teicoplanin £ 0.06–1 0.125 0.125
Streptococcus spp. (26) AZD2563 0.125–1 0.5 1
Linezolid 0.25–1 1 1
Quinupristin–dalfopristin 0.25–2 1 2
Levofloxacin 0.25–4 1 2
Clarithromycin £ 0.06–2 £ 0.06 1
Vancomycin 0.5–1 1 1
Teicoplanin £ 0.06–0.125 £ 0.06 0.125
Corynebacterium spp. (35) AZD2563 0.125–4 0.25 1
Linezolid 0.06–4 0.25 1
Quinupristin–dalfopristin 0.125–8 0.25 4
Levofloxacin 0.06–32 0.5 32
Clarithromycin 0.06 to > 128 0.5 8
Vancomycin 0.06–4 0.5 1
Teicoplanin 0.5–2 1 2
Enterobacteriaceae (90)a
and non-fermenting
Gram-negative bacillib
AZD2563
Linezolid
Quinupristin–dalfopristin
> 128
> 128
> 128
> 128
> 128
> 128
> 128
> 128
> 128
Moraxella catarrhalis (28) AZD2563 1–64 16 32
Linezolid 2–16 4 4
Quinupristin–dalfopristin 0.125–2 1 2
Levofloxacin 0.015–0.5 0.06 0.06
Clarithromycin 0.008–0.25 0.008 0.03
Vancomycin 2 to > 128 64 > 128
Teicoplanin 8–64 32 64
Haemophilus influenzae (40) AZD2563 32 to > 128 > 128 > 128
Linezolid 2–128 16 32
Quinupristin–dalfopristin 1–16 4 8
Levofloxacin 0.06 0.06 0.06
Clarithromycin 1–16 2 8
Vancomycin 16–128 64 128
Teicoplanin 16–128 64 128
aEscherichia coli (10), Citrobacter freundii (10), Citrobacter diversus (10), Klebsiella pneumoniae (10), Enterobacter cloacae
(10), Enterobacter aerogenes (10), Serratia marcescens (10), Proteus vulgaris (10), Proteus mirabilis (10).
bPseudomonas aeruginosa (10), Burkholderia cepacia (10).
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most of the staphylococci and enterococci
showed a bacteriostatic response. The data for
linezolid reinforced the notion of a species-
specific bactericidal effect, as described previ-
ously [12].
Time–kill studies
AZD2563 demonstrated bacteriostatic activity
(a reduction of at least three logs) against the
staphylococci and enterococci tested. There was
some limited reduction in the numbers of pneu-
mococci (1.40 and 0.88 log), in agreement with
results reported by Lin et al. [13], but not suf-
ficient for the agent to be considered truly
bactericidal [14]. AZD2563 and linezolid showed
similar time–kill kinetics against the six strains
tested (Fig. 3).
Effects of miscellaneous factors on activity
The presence of human serum (10% or 25% v ⁄v),
a varying pH in the medium (pH 5, 6, 7 or 8) or an
altered bacterial challenge (103, 104, 105 or
106 CFU ⁄ inoculum spot) did not significantly
alter the MICs of AZD2563. Results were within
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Fig. 2. Cumulative percentage susceptibilities for AZD2563 and linezolid against recent clinical isolates (MR, Methicillin-
resistant; MS, Methicillin-susceptible).
Table 2. MBCs of AZD2563 and
linezolid expressed as multiples of
the MIC
Organism (no. tested) Antibiotic
% of strains with MBC ⁄
MIC ratio of:
1 2 4 8 16 > 16
Staphylococcus aureus (10) AZD2563 10 10 80
Linezolid 10 90
Staphylococcus epidermidis (10) AZD2563 10 20 10 60
Linezolid 10 10 10 30 30 10
Enterococcus faecium (9) AZD2563 33 66
Linezolid 11 89
Enterococcus faecalis (10) AZD2563 10 10 10 40 30
Linezolid 10 20 30 40
Streptococcus pneumoniae (18) AZD2563 44 22 18 18
Linezolid 5 33 22 11 5
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the range of experimental error, and no trends
were noted. Different media, either agar or broth,
had no significant effect on the MICs of AZD2563,
but there was a slight tendency for the MICs
determined on IsoSensitest medium to be one or
two dilutions more potent.
D I S C U S S I O N
The data presented in this study show that
AZD2563 was consistently active against all
Gram-positive aerobic isolates tested, regardless
of patterns of resistance to other agents, and
were in agreement with other data presented
elsewhere [15–24]. Results obtained for linezolid
were also in accordance with those obtained
from studies reported previously [25–28]. Oxa-
zolidinones possess uniform potency against
Gram-positive isolates, with only small varia-
tions in MIC. A potential advantage of AZD2563
over linezolid would be a downward shift in
the MIC distribution curve, with possible
important implications (e.g., in dosage selec-
tion). The modest bactericidal activity of
AZD2563 agreed with results obtained with
linezolid [28]. However, clinical data from
linezolid trials have shown that microbiological
eradication rates are essentially equivalent to
clinical response.
In the present study, both agar dilution and
broth microdilution methods were utilised. Pre-
liminary quality control ranges for AZD2563 MIC
and disk diffusion methods have been established
[29], and seem to be acceptable. The oxazolidi-
nones represent a valuable addition to the anti-
bacterial options at a time when infections caused
by multiresistant Gram-positive bacteria continue
to increase. AZD2563 is the most recent member
of this class to enter development. Activity
against Gram-positive bacteria, combined with
the potential for once-daily dosing by either
the oral or parenteral route, demonstrates the
potential for reliable activity and convenience of
administration.
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